CNS Pharmaceuticals (CNSP) Expected to Announce Quarterly Earnings on Monday

CNS Pharmaceuticals (NASDAQ:CNSP) will likely be releasing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect CNS Pharmaceuticals to post earnings of ($5.37) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

CNS Pharmaceuticals Stock Performance

Shares of CNSP opened at $2.44 on Friday. CNS Pharmaceuticals has a one year low of $2.06 and a one year high of $34.80. The stock’s fifty day moving average is $3.85 and its 200-day moving average is $6.18. The firm has a market capitalization of $1.51 million, a price-to-earnings ratio of -0.08 and a beta of 2.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $20.00.

Institutional Trading of CNS Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNSP. Boothbay Fund Management LLC bought a new stake in CNS Pharmaceuticals during the fourth quarter worth approximately $71,000. Ikarian Capital LLC bought a new position in shares of CNS Pharmaceuticals in the fourth quarter valued at $241,000. Finally, Armistice Capital LLC acquired a new stake in shares of CNS Pharmaceuticals during the 2nd quarter valued at $335,000. 14.02% of the stock is owned by institutional investors and hedge funds.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.